Polyrizon (PLRZ) Non-Current Assets (2023 - 2025)
Polyrizon's (PLRZ) quarterly Non-Current Assets came in at $8.6 million in Q4 2025, up 196.37% YoY from $2.9 million in Q4 2024, and up 216.85% on a QoQ basis from $2.7 million in Q2 2025.
Polyrizon (PLRZ) Non-Current Assets (2023 - 2025) Analysis & Trends
Polyrizon (PLRZ) has 3 years of Non-Current Assets data on file, last reported at $8.6 million in Q4 2025.
- Quarterly Non-Current Assets rose 196.37% year-over-year to $8.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14.7 million (changed N/A YoY) and the FY2025 annual result came in at $8.6 million, up 196.37% from the prior year.
- Non-Current Assets grew to $8.6 million in Q4 2025, from $2.7 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $8.6 million in Q4 2025 to a low of $505000.0 in Q4 2023.
- A 3-year average of $3.7 million and a median of $2.8 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2024 — Non-Current Assets soared 473.07% — and 2025, when it soared 196.37%.
- Tracing PLRZ's Non-Current Assets over 3 years: stood at $505000.0 in 2023, then soared by 473.07% to $2.9 million in 2024, then soared by 196.37% to $8.6 million in 2025.
- The last three Non-Current Assets figures came in at $8.6 million (Q4 2025), $2.7 million (Q2 2025), and $2.9 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 18.06 Bn |
| 10 | Polyrizon | 7.13 Mn | -4.36 Mn | - | 8.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.58 Mn |
| Jun 30, 2025 | 2.71 Mn |
| Dec 31, 2024 | 2.89 Mn |
| Dec 31, 2023 | 505,000.00 |